Daniel F Rubinstein, 845920 Los Pueblos Dr, El Paso, TX 79912

2001000, Jul 12, 2001

Feb 28, 2001

09/795738

Alan Rubinstein - Los Angeles CA, US
Daniel Rubinstein - Brookline MA, US

C12N007/04

435/236000

Recombinant proteins, manufactured with genetic engineering techniques, like its counterpart human derived proteins, for example, recombinant Factor VIII have the potential for transmission of viruses and bacteria which are used in the process. This invention demonstrates that one may dry heat at high temperature, the lyophilized final Factor VIII product even at high temperatures and still show significant VIII:C activity. Such terminal dry heat will assure that there has been recontamination.

2003006, Apr 10, 2003

Nov 8, 2002

10/290882

Alan Rubinstein - Los Angeles CA, US
Daniel Rubinstein - Brookline MA, US

C12N001/02
C12P021/04
C12N001/06

435/261000, 435/259000, 435/069600

Recombinant proteins, manufactured with genetic engineering techniques, like its counterpart human derived proteins, for example, recombinant Factor VIII have the potential for transmission of viruses and bacteria which are used in the process. This invention demonstrates that one may dry heat at high temperature, the lyophilized final Factor VIII product even at high temperatures and still show significant VIII:C activity. Such terminal dry heat will assure that there has been recontamination.

5698430, Dec 16, 1997

Nov 14, 1994

8/339343

Alan I. Rubinstein - Los Angeles CA
Daniel B. Rubinstein - Brookline MA

C12N 704
C12N 706
C12N 702
A61K 3921

435236

A method of producing a vaccine comprising providing a quantity of the disease-causing entity, treating the quantity to remove or disrupt a majority of the nucleic acid present in the quantity sufficient to render the quantity non-infective while maintaining the structure of the proteins and glycoproteins on the surface of the entity to render the vaccine protective. A method of producing a vaccine to human pathogenic retroviruses comprising the steps of partially solubilizing a quantity of the virus to produce a suspension, adding a proteinase to the suspension to release viral nucleic acids from the viral coat proteins, treating the suspension to disrupt or remove sufficient viral nucleic acids to render the suspension substantially or completely non-infective and verifying the sufficient disruption or removal of viral nucleic acids from the suspension.